Macrophage activation syndrome associated with systemic lupus erythematosus treated successfully with the combination of steroid pulse, immunoglobulin and tacrolimus

Romanian Journal of Internal Medicine = Revue Roumaine De Médecine Interne
Natsuki Aoyama-MaedaYoshio Terada

Abstract

Macrophage activation syndrome (MAS), a variant of secondary hemophagocyticlymphohistiocytosis, is a potentially life-threatening complication of inflammatory and autoimmune diseases. We present a case of MAS as a rare manifestation of systemic lupus erythematosus. Although initial treatment with corticosteroid, with or without cyclosporine A, is justified in patients with MAS, evidence regarding the effectiveness of this treatment protocol remains to be clarified. Our patient was successfully treated with a combination of intravenous immunoglobulin therapy and intravenous methyl predonisolone pulse therapy, which was followed by a course of oral prednisolone and oral tacrolimus. Based on our experience, we propose tacrolimus to provide a more useful adjuvant treatment to corticosteroid therapy than cyclosporine A.

References

Nov 1, 1982·Arthritis and Rheumatism·E M TanR J Winchester
Aug 29, 2006·Pediatric Blood & Cancer·Jan-Inge HenterGritta Janka
Aug 11, 2011·Blood·Michael B JordanKenneth L McClain
Jun 12, 2012·Arthritis Research & Therapy·Sebastian Fn BodeStephan Ehl
Apr 24, 2014·Arthritis & Rheumatology·Shunichi Kumakura, Yohko Murakawa
Oct 3, 2015·Autoimmunity Reviews·Jennifer HannahDavid D'Cruz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

© 2022 Meta ULC. All rights reserved